Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2025 07:55 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

Site initiation for Phase 2a DKD trial marks a key milestone for ZyVersa, and for development of VAR 200, a first-in-class treatment for kidney disease.